Anna Wesołowska
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Anna Wesołowska has a total of 284 co-authors. Here are the top co-authors by number of shared publications:
- Magdalena Jastrzębska-Więsek
Faculty of Pharmacy, Jagiellonian University Medical College, Krakow, Poland
48 shared publications - Andrzej J. Bojarski
Department of Medicinal Chemistry, Maj Institute of Pharmacology, Polish Academy of Sciences, Kraków, Poland
32 shared publications - Marcin Kołaczkowski
Department of Medicinal Chemistry, Faculty of Pharmacy, Jagiellonian University Medical College, 9 Medyczna Street, 30-688 Kraków, Poland
31 shared publications Anna Partyka
Jagiellonian University Medical College, Department of Clinical Pharmacy, Kraków, Poland
30 shared publications- Anna Partyka
Faculty of Pharmacy, Jagiellonian University Medical College, Krakow, Poland
29 shared publications - Grzegorz Satała
Maj Institute of Pharmacology, Polish Academy of Sciences, 12 Smętna Street, 31-343 Kraków, Poland
28 shared publications
Latest Publications
- Open Access
- 15 May 2026
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 315, 118966
New chalcogen-optimized 1,3,5-triazines as dual 5-HT6R/FAAH modulators: A versatile approach to neurodegenerative disorders
- 15 May 2026
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 315, 118966
Open AccessNew chalcogen-optimized 1,3,5-triazines as dual 5-HT6R/FAAH modulators: A versatile approach to neurodegenerative disorders
- Open Access
- 5 August 2025
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 298, 118026
The first-in-class 1,3,5-triazine-derived dual 5-HT6R/FAAH modulators in search for potential drug against neurodegenerative diseases with cognitive impairment
- 5 August 2025
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 298, 118026
Open AccessThe first-in-class 1,3,5-triazine-derived dual 5-HT6R/FAAH modulators in search for potential drug against neurodegenerative diseases with cognitive impairment
- Open Access
- 30 May 2025
- Published by Springer Nature in Pharmacological Reports
- Vol. 77 (4) , 1142
Correction: Compound PZ-1262, a 4-isoquinoline-sulfonamide analog of Brexpiprazole, produces potential antidepressant, anxiolytic and procognitive effects in rodent models
- 30 May 2025
- Published by Springer Nature in Pharmacological Reports
- Vol. 77 (4) , 1142
Open AccessCorrection: Compound PZ-1262, a 4-isoquinoline-sulfonamide analog of Brexpiprazole, produces potential antidepressant, anxiolytic and procognitive effects in rodent models
- 11 March 2025
- Published by Springer Nature in Pharmacological Reports
- Vol. 77 (3) , 689-702
Compound PZ-1262, a 4-isoquinoline-sulfonamide analog of Brexpiprazole, produces potential antidepressant, anxiolytic and procognitive effects in rodent models
Background Novel antipsychotics are characterized by multitarget profile of action, affecting among others, dopamine and serotonin receptors. In a series of experiments, we designed, synthesized and examined two new isoquinoline-sulfonamide analogs of the modern multitarget antipsychotics aripiprazole and brexpiprazole, compounds PZ-1262 and PZ-1264. We hypothesized that the 4-isoquinolinesulfonamide moiety, derived from the structure of 5-HT6 receptor antagonists, would provide compounds with enhanced activity at 5-HT6 receptors, along with partial agonistic activity at 5-HT1A and D2 receptors. Methods The receptor binding profile, functional activity, and metabolic stability of PZ-1262 and PZ-1264 were evaluated through in vitro assays. Potential antipsychotic, antidepressant, anxiolytic, and pro-cognitive effects were assessed using in vivo behavioral tests in rodents. Results In vitro, PZ compounds demonstrated partial agonistic activity at 5-HT1A receptor, antagonistic activity at D2 and D3 as well as 5-HT2A, 5-HT6 and 5-HT7 receptors and metabolic stability. In vivo, both compounds enhanced phencyclidine-induced hyperactivity in rats and decreased immobility time in the forced swim test in mice, without influencing spontaneous locomotor activity. In the novel object recognition test in rats, they demonstrated pro-cognitive effects in phencyclidine disturbed conditions. PZ-1262 potentiated D-amphetamine-induced hyperactivity, exhibited anxiolytic-like effects in the four plates test in mice, and demonstrated significant brain penetration. Conclusions The complex pharmacodynamic profile translated into the useful psychotropic effects. While the compounds potentiated D-amphetamine- and phencyclidine-induced hyperactivity, this action could be regarded as a desired activating effect rather than evidence against antipsychotic-like efficacy. Present findings point to PZ-1262 as a more promising lead compound for further research.
- 11 March 2025
- Published by Springer Nature in Pharmacological Reports
- Vol. 77 (3) , 689-702
Compound PZ-1262, a 4-isoquinoline-sulfonamide analog of Brexpiprazole, produces potential antidepressant, anxiolytic and procognitive effects in rodent models
Background Novel antipsychotics are characterized by multitarget profile of action, affecting among others, dopamine and serotonin receptors. In a series of experiments, we designed, synthesized and examined two new isoquinoline-sulfonamide analogs of the modern multitarget antipsychotics aripiprazole and brexpiprazole, compounds PZ-1262 and PZ-1264. We hypothesized that the 4-isoquinolinesulfonamide moiety, derived from the structure of 5-HT6 receptor antagonists, would provide compounds with enhanced activity at 5-HT6 receptors, along with partial agonistic activity at 5-HT1A and D2 receptors. Methods The receptor binding profile, functional activity, and metabolic stability of PZ-1262 and PZ-1264 were evaluated through in vitro assays. Potential antipsychotic, antidepressant, anxiolytic, and pro-cognitive effects were assessed using in vivo behavioral tests in rodents. Results In vitro, PZ compounds demonstrated partial agonistic activity at 5-HT1A receptor, antagonistic activity at D2 and D3 as well as 5-HT2A, 5-HT6 and 5-HT7 receptors and metabolic stability. In vivo, both compounds enhanced phencyclidine-induced hyperactivity in rats and decreased immobility time in the forced swim test in mice, without influencing spontaneous locomotor activity. In the novel object recognition test in rats, they demonstrated pro-cognitive effects in phencyclidine disturbed conditions. PZ-1262 potentiated D-amphetamine-induced hyperactivity, exhibited anxiolytic-like effects in the four plates test in mice, and demonstrated significant brain penetration. Conclusions The complex pharmacodynamic profile translated into the useful psychotropic effects. While the compounds potentiated D-amphetamine- and phencyclidine-induced hyperactivity, this action could be regarded as a desired activating effect rather than evidence against antipsychotic-like efficacy. Present findings point to PZ-1262 as a more promising lead compound for further research.
- 16 December 2024
- Published by Springer Nature in Pharmacological Reports
- Vol. 77 (1) , 158-171
Advanced pharmacological and pharmacokinetic evaluation of 1,3 dimethylpurine-2,6-dione derivative (GR-14) with prominent mood-modulating activity in rats
Background Research on new candidates for antidepressant/anxiolytic drugs from the long-chain arylpiperazines (LCAPs) group containing a 1,3-dimethylpurine-2,6-dione as a terminal amide fragment fits into the modern exploration trend. This study aimed to examine, for the first time in male Wistar rats, pharmacodynamic (antidepressant- and anxiolytic-like) and pharmacokinetic properties of 7-(5-(4-(3-chlorophenyl)piperazin-1-yl)pentyl)-1,3-dimethyl-3,7-dihydro-1 H-purine-2,6-dione hydrochloride (GR-14). Methods Antidepressant- and anxiolytic-like activities have been assessed in the forced swim test (FST) and Vogel conflict drinking test, respectively. The pharmacokinetic characteristics of GR-14, its distribution into rat tissues, and several in vitro ADME-Tox parameters (hepatocytotoxic, neurocytotoxic, metabolic stability) have been defined. Results GR-14 produces strong and dose-dependent antidepressant- and anxiolytic-like effects in both tests used. Pharmacokinetic findings demonstrate that GR-14 reveals linear pharmacokinetics tested after intravenous (iv) and was rapidly absorbed after oral (po) administration. It rapidly crosses the blood-brain barrier (BBB) which is vital for therapeutic effects in vivo in psychiatric diseases, depression, and anxiety. Moreover, it is slowly eliminated from the brain, maintaining concentrations higher than those in plasma at the last time point measured. Further studies have also shown that GR-14 is an average high-clearance drug in rat liver microsomes and exerts neither hepatocytotoxic nor neurocytotoxic effects in vitro. Conclusion The tested derivative GR-14 presents prominent mood-modulating activity in rats and has promising pharmacokinetic parameters and a good safety profile. The beneficial pharmacology and pharmacokinetics of GR-14 in vivo are in high concordance with its profile in vitro, thus underlining very hopeful properties to support the early development process. Graphical Abstract
- 16 December 2024
- Published by Springer Nature in Pharmacological Reports
- Vol. 77 (1) , 158-171
Advanced pharmacological and pharmacokinetic evaluation of 1,3 dimethylpurine-2,6-dione derivative (GR-14) with prominent mood-modulating activity in rats
Background Research on new candidates for antidepressant/anxiolytic drugs from the long-chain arylpiperazines (LCAPs) group containing a 1,3-dimethylpurine-2,6-dione as a terminal amide fragment fits into the modern exploration trend. This study aimed to examine, for the first time in male Wistar rats, pharmacodynamic (antidepressant- and anxiolytic-like) and pharmacokinetic properties of 7-(5-(4-(3-chlorophenyl)piperazin-1-yl)pentyl)-1,3-dimethyl-3,7-dihydro-1 H-purine-2,6-dione hydrochloride (GR-14). Methods Antidepressant- and anxiolytic-like activities have been assessed in the forced swim test (FST) and Vogel conflict drinking test, respectively. The pharmacokinetic characteristics of GR-14, its distribution into rat tissues, and several in vitro ADME-Tox parameters (hepatocytotoxic, neurocytotoxic, metabolic stability) have been defined. Results GR-14 produces strong and dose-dependent antidepressant- and anxiolytic-like effects in both tests used. Pharmacokinetic findings demonstrate that GR-14 reveals linear pharmacokinetics tested after intravenous (iv) and was rapidly absorbed after oral (po) administration. It rapidly crosses the blood-brain barrier (BBB) which is vital for therapeutic effects in vivo in psychiatric diseases, depression, and anxiety. Moreover, it is slowly eliminated from the brain, maintaining concentrations higher than those in plasma at the last time point measured. Further studies have also shown that GR-14 is an average high-clearance drug in rat liver microsomes and exerts neither hepatocytotoxic nor neurocytotoxic effects in vitro. Conclusion The tested derivative GR-14 presents prominent mood-modulating activity in rats and has promising pharmacokinetic parameters and a good safety profile. The beneficial pharmacology and pharmacokinetics of GR-14 in vivo are in high concordance with its profile in vitro, thus underlining very hopeful properties to support the early development process. Graphical Abstract
- Open Access
- 30 July 2023
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 259, 115695
Synthesis, computational and experimental pharmacological studies for (thio)ether-triazine 5-HT6R ligands with noticeable action on AChE/BChE and chalcogen-dependent intrinsic activity in search for new class of drugs against Alzheimer's disease
- 30 July 2023
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 259, 115695
Open AccessSynthesis, computational and experimental pharmacological studies for (thio)ether-triazine 5-HT6R ligands with noticeable action on AChE/BChE and chalcogen-dependent intrinsic activity in search for new class of drugs against Alzheimer's disease
- Open Access
- 28 July 2023
- Published by Polish Pharmaceutical Society in Acta Poloniae Pharmaceutica - Drug Research
- Vol. 80 (3) , 373-387
Reliable HPLC-UV method for therapeutic levetiracetam monitoring in serum and cerebrospinal fluid of patients with epilepsy
- 28 July 2023
- Published by Polish Pharmaceutical Society in Acta Poloniae Pharmaceutica - Drug Research
- Vol. 80 (3) , 373-387
Open AccessReliable HPLC-UV method for therapeutic levetiracetam monitoring in serum and cerebrospinal fluid of patients with epilepsy
- Open Access
- 20 January 2023
- Published by MDPI AG in Pharmaceuticals
- Vol. 16 (2) , 154
Selective 5-HT6 Receptor Ligands (Agonist and Antagonist) Show Different Effects on Antipsychotic Drug-Induced Metabolic Dysfunctions in Rats
It is estimated that in patients taking antipsychotic drugs (APDs), metabolic syndrome occurs 2–3 times more often than in the general population. It manifests itself in abdominal obesity, elevated glucose concentration, and dyslipidemia. Despite the high prevalence of this disorder, only a small percentage of patients receive appropriate and effective treatment, and none of the available methods for preventing or treating APD-induced metabolic side effects is satisfactory. A promising supplement to antipsychotic therapy appears to be ligands of the serotonin 6 (5-HT6) receptor. The present study aimed to examine the chronic effects of the selected APDs (haloperidol, risperidone, olanzapine), administered alone and in combination with a selective 5-HT6 agonist (WAY-181187) or antagonist (SB-742457), on weight gain, food intake, serum lipid profile, glucose level, and a spectrum of hormones derived from adipose (leptin, adiponectin) and gastrointestinal (insulin, ghrelin) tissue in rats. SB-742457 inhibited increased weight gain and alleviated hyperglycemia induced by APDs more strongly than did WAY-181187, but also intensified dyslipidemia. WAY-181187 tended to improve the lipid profile, but increased the glucose level. The greatest benefits were obtained when WAY-181187 or SB-742457 were co-administered with haloperidol. It is difficult to assess whether the modification of the serum levels of insulin, leptin, ghrelin, and adiponectin depended on the treatment applied or other drug-independent factors; therefore, further research is needed.
- 20 January 2023
- Published by MDPI AG in Pharmaceuticals
- Vol. 16 (2) , 154
Open AccessSelective 5-HT6 Receptor Ligands (Agonist and Antagonist) Show Different Effects on Antipsychotic Drug-Induced Metabolic Dysfunctions in Rats
It is estimated that in patients taking antipsychotic drugs (APDs), metabolic syndrome occurs 2–3 times more often than in the general population. It manifests itself in abdominal obesity, elevated glucose concentration, and dyslipidemia. Despite the high prevalence of this disorder, only a small percentage of patients receive appropriate and effective treatment, and none of the available methods for preventing or treating APD-induced metabolic side effects is satisfactory. A promising supplement to antipsychotic therapy appears to be ligands of the serotonin 6 (5-HT6) receptor. The present study aimed to examine the chronic effects of the selected APDs (haloperidol, risperidone, olanzapine), administered alone and in combination with a selective 5-HT6 agonist (WAY-181187) or antagonist (SB-742457), on weight gain, food intake, serum lipid profile, glucose level, and a spectrum of hormones derived from adipose (leptin, adiponectin) and gastrointestinal (insulin, ghrelin) tissue in rats. SB-742457 inhibited increased weight gain and alleviated hyperglycemia induced by APDs more strongly than did WAY-181187, but also intensified dyslipidemia. WAY-181187 tended to improve the lipid profile, but increased the glucose level. The greatest benefits were obtained when WAY-181187 or SB-742457 were co-administered with haloperidol. It is difficult to assess whether the modification of the serum levels of insulin, leptin, ghrelin, and adiponectin depended on the treatment applied or other drug-independent factors; therefore, further research is needed.
- Open Access
- 3 November 2022
- Published by Polish Pharmaceutical Society in Farmacja Polska
- Vol. 78 (8) , 415-429
Monitoring of tacrolimus concentration after kidney or heart transplantation - the importance of intra-subject variability parameters
Przedmiot badań. Właściwie prowadzona immunosupresja w terapii potransplantacyjnej jest warunkiem niezbędnym do zminimalizowania ryzyka odrzucenia narządu. Cel badań. Analiza stężeń minimalnych (Cssmin) takrolimusu (TAC) w stanie stacjonarnym, w pierwszym miesiącu po przeszczepie serca lub nerki. Wyliczono współczynnik zmienności wewnątrzosobniczej (CV), poszukiwano korelacji z parametrami biochemicznymi oraz przedstawiono zalecenia/aktualne wytyczne optymalizacji dawkowania TAC na podstawie baz medycznych opartych na faktach (EBM). Materiał i metody. Do retrospektywnej analizy wybrano 24 pacjentów w wieku 24-79 lat (średnia 47,1±13,9 lat); 12 po przeszczepie serca i 12 po przeszczepie nerki. Dawkowanie TAC było jednakowe w grupach pacjentów oraz nie ulegało zmianie w trakcie analizy (pierwszy miesiąc); w przypadku biorców serca wynosiło 2 mg/dobę oraz 1 mg/dobę u biorców nerki. Pomiar Cssmin TAC w pełnej krwi (stan stacjonarny) wykonano czterokrotnie u wszystkich pacjentów; pierwszy w 15 dobie leczenia, drugi w 16-18, trzeci w 17-19, czwarty w 18-21. Do analizy stężenia TAC zastosowano test immunologiczny QMS Tacrolimus stosując automatyczny analizator biochemiczny Indiko Plus. Wyniki. Mediana wartości Cssmin TAC wynosiła 6,9-15,6 ng/mL po przeszczepie serca oraz 8,7-16,0 ng/mL po przeszczepie nerki. Zakres CV pacjentów po przeszczepie serca był 4-60%, natomiast po przeszczepie nerki 8-40%. CV>30% (wyższe prawdopodobieństwo ryzyka ostrego odrzucenia) po przeszczepie serca dotyczył 25% pacjentów, po przeszczepie nerki 15%. Analiza przeżycia narządu u biorców serca i nerki wykazała odpowiednio 83% i 100% po średnio 2,7±0,5 i 3,25±2,5 latach od transplantacji. Nie wykazano istotnych korelacji (p > 0,05) pomiędzy CV a wybranymi parametrami biochemicznymi. Wnioski. CV>30% może wskazywać na dużą zmienność w farmakokinetyce TAC, a tym samym konieczność optymalizacji dawkowania/parametrów fizjologicznych wpływających na wartość stężenia. Konieczna wydaje się poprawa personalizacji terapii immunosupresyjnej z TAC, uwzględniająca indywidualne parametry zmienności zewnątrz- i wewnątrzosobniczej w celu uzyskania lepszych efektów oraz uniknięcia ostrego/przewlekłego odrzucenia, przyśpieszonej w czasie utraty przeszczepu i/lub występowania dodatkowych działań niepożądanych TAC.
- 3 November 2022
- Published by Polish Pharmaceutical Society in Farmacja Polska
- Vol. 78 (8) , 415-429
Open AccessMonitoring of tacrolimus concentration after kidney or heart transplantation - the importance of intra-subject variability parameters
Przedmiot badań. Właściwie prowadzona immunosupresja w terapii potransplantacyjnej jest warunkiem niezbędnym do zminimalizowania ryzyka odrzucenia narządu. Cel badań. Analiza stężeń minimalnych (Cssmin) takrolimusu (TAC) w stanie stacjonarnym, w pierwszym miesiącu po przeszczepie serca lub nerki. Wyliczono współczynnik zmienności wewnątrzosobniczej (CV), poszukiwano korelacji z parametrami biochemicznymi oraz przedstawiono zalecenia/aktualne wytyczne optymalizacji dawkowania TAC na podstawie baz medycznych opartych na faktach (EBM). Materiał i metody. Do retrospektywnej analizy wybrano 24 pacjentów w wieku 24-79 lat (średnia 47,1±13,9 lat); 12 po przeszczepie serca i 12 po przeszczepie nerki. Dawkowanie TAC było jednakowe w grupach pacjentów oraz nie ulegało zmianie w trakcie analizy (pierwszy miesiąc); w przypadku biorców serca wynosiło 2 mg/dobę oraz 1 mg/dobę u biorców nerki. Pomiar Cssmin TAC w pełnej krwi (stan stacjonarny) wykonano czterokrotnie u wszystkich pacjentów; pierwszy w 15 dobie leczenia, drugi w 16-18, trzeci w 17-19, czwarty w 18-21. Do analizy stężenia TAC zastosowano test immunologiczny QMS Tacrolimus stosując automatyczny analizator biochemiczny Indiko Plus. Wyniki. Mediana wartości Cssmin TAC wynosiła 6,9-15,6 ng/mL po przeszczepie serca oraz 8,7-16,0 ng/mL po przeszczepie nerki. Zakres CV pacjentów po przeszczepie serca był 4-60%, natomiast po przeszczepie nerki 8-40%. CV>30% (wyższe prawdopodobieństwo ryzyka ostrego odrzucenia) po przeszczepie serca dotyczył 25% pacjentów, po przeszczepie nerki 15%. Analiza przeżycia narządu u biorców serca i nerki wykazała odpowiednio 83% i 100% po średnio 2,7±0,5 i 3,25±2,5 latach od transplantacji. Nie wykazano istotnych korelacji (p > 0,05) pomiędzy CV a wybranymi parametrami biochemicznymi. Wnioski. CV>30% może wskazywać na dużą zmienność w farmakokinetyce TAC, a tym samym konieczność optymalizacji dawkowania/parametrów fizjologicznych wpływających na wartość stężenia. Konieczna wydaje się poprawa personalizacji terapii immunosupresyjnej z TAC, uwzględniająca indywidualne parametry zmienności zewnątrz- i wewnątrzosobniczej w celu uzyskania lepszych efektów oraz uniknięcia ostrego/przewlekłego odrzucenia, przyśpieszonej w czasie utraty przeszczepu i/lub występowania dodatkowych działań niepożądanych TAC.
- Open Access
- 30 May 2022
- Published by Polish Pharmaceutical Society in Farmacja Polska
- Vol. 78 (3) , 111-122
Comparative analysis of valproic acid concentrations in terms of dosing and clinical effect monitoring in different age patients with diagnosed epilepsy
- 30 May 2022
- Published by Polish Pharmaceutical Society in Farmacja Polska
- Vol. 78 (3) , 111-122
Open AccessComparative analysis of valproic acid concentrations in terms of dosing and clinical effect monitoring in different age patients with diagnosed epilepsy